Deutsche Bank AG Invests $1.89 Million in Stoke Therapeutics, Inc. $STOK

Deutsche Bank AG bought a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 57,784 shares of the company’s stock, valued at approximately $1,891,000.

Several other hedge funds have also bought and sold shares of STOK. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Stoke Therapeutics by 5.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after buying an additional 1,149 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Stoke Therapeutics by 21.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after buying an additional 293,072 shares during the last quarter. Jane Street Group LLC lifted its position in shares of Stoke Therapeutics by 125.2% in the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock valued at $179,000 after buying an additional 15,001 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Stoke Therapeutics by 26.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 25,655 shares of the company’s stock worth $291,000 after acquiring an additional 5,398 shares during the period. Finally, Rhumbline Advisers boosted its stake in shares of Stoke Therapeutics by 33.9% during the 2nd quarter. Rhumbline Advisers now owns 66,419 shares of the company’s stock worth $754,000 after acquiring an additional 16,820 shares during the period.

Stoke Therapeutics Trading Down 3.0%

NASDAQ:STOK opened at $31.62 on Friday. The stock has a 50 day simple moving average of $31.22 and a 200 day simple moving average of $32.26. The stock has a market cap of $2.04 billion, a P/E ratio of -9.47 and a beta of 1.20. Stoke Therapeutics, Inc. has a 1-year low of $18.80 and a 1-year high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The firm had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. As a group, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -3.52 EPS for the current year.

Analysts Set New Price Targets

STOK has been the topic of a number of research analyst reports. Weiss Ratings restated a “sell (d)” rating on shares of Stoke Therapeutics in a research note on Friday, August 7th. BTIG Research reaffirmed a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research report on Monday, May 11th. The Goldman Sachs Group started coverage on shares of Stoke Therapeutics in a report on Monday, July 13th. They issued a “buy” rating and a $44.00 price objective on the stock. Chardan Capital restated a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Finally, Guggenheim reaffirmed a “buy” rating and set a $60.00 target price on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Stoke Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.25.

Insider Activity at Stoke Therapeutics

In related news, insider Barry Ticho sold 4,767 shares of the business’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $152,687.01. Following the completion of the transaction, the insider owned 25,655 shares of the company’s stock, valued at $821,729.65. The trade was a 15.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Edward M. Md Kaye sold 12,567 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total transaction of $402,521.01. Following the completion of the transaction, the director owned 124,557 shares of the company’s stock, valued at $3,989,560.71. The trade was a 9.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 30,623 shares of company stock worth $953,765. Company insiders own 9.60% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.